A review of ERCC1 gene in bladder cancer: Implications for carcinogenesis and resistance to chemoradiotherapy

Advances in Urology

Volumn , Issue , 2012, Pages

  Kawashima, Atsunari ^a   Takayama, Hitoshi ^a   Tsujimura, Akira ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855180167     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/812398     Document Type: Review

References (54)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA Cancer Journal for Clinicians 2009 59 4 225 249
2. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
3. Boffetta P., Tobacco smoking and risk of bladder cancer Scandinavian Journal of Urology and Nephrology 2008 42 supplement 218 45 54
4. Zeegers M. P., Tan F. E., Dorant E., van Den Brandt P. A., The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies Cancer 2000 89 3 630 639 (Pubitemid 30640110)
5. Kogevinas M., t Mannetje A., Cordier S., Ranft U., Gonzlez C. A., Vineis P., Chang-Claude J., Lynge E., Wahrendorf J., Tzonou A., Jckel K. H., Serra C., Porru S., Hours M., Greiser E., Boffetta P., Occupation and bladder cancer among men in Western Europe Cancer Causes and Control 2003 14 10 907 914 (Pubitemid 38091211)
6. García-Closas M., Malats N., Real F. X., Welch R., Kogevinas M., Chatterjee N., Pfeiffer R., Silverman D., Dosemeci M., Tardn A., Serra C., Carrato A., Garca-Closas R., Castao-Vinyals G., Chanock S., Yeager M., Rothman N., Genetic variation in the nucleotide excision repair pathway and bladder cancer risk Cancer Epidemiology Biomarkers and Prevention 2006 15 3 536 542
7. Gogna N. K., Matthews J. H., Turner S. L., Mameghan H., Duchesne G. M., Spry N., Berry M. P., Keller J., Tripcony L., Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group Radiotherapy and Oncology 2007 83 2 215 (Pubitemid 46776916)
8. Stein J. P., Lieskovsky G., Cote R., Groshen S., Feng A. C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., Raghavan D., Skinner D. G., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients Journal of Clinical Oncology 2001 19 3 666 675 (Pubitemid 32120143)
9. Choudhury A., Nelson L. D., Teo M. T., Chilka S., Bhattarai S., Johnston C. F., Elliott F., Lowery J., Taylor C. F., Churchman M., Bentley J., Knowles M. A., Harnden P., Bristow R. G., Bishop D. T., Kiltie A. E., MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer Cancer Research 2010 70 18 7017 7026
10. Usanova S., Piée-Staffa A., Sied U., Thomale J., Schneider A., Kaina B., Kberle B., Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression Molecular Cancer 2010 9, article 248
11. Park C. H., Bessho T., Matsunaga T., Sancar A., Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease Journal of Biological Chemistry 1995 270 39 22657 22660
12. Gregg S. Q., Robinson A. R., Niedernhofer L. J., Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease DNA Repair 2011 10 7 781 791
13. Ahmad A., Robinson A. R., Duensing A., Van Drunen E., Beverloo H. B., Weisberg D. B., Hasty P., Hoeijmakers J. H. J., Niedernhofer L. J., ERCC1-XPF endonuclease facilitates DNA double-strand break repair Molecular and Cellular Biology 2008 28 16 5082 5092
14. Kuraoka I., Kobertz W. R., Ariza R. R., Biggerstaff M., Essigmann J. M., Wood R. D., Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease Journal of Biological Chemistry 2000 275 34 26632 26636
15. Olaussen K. A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H. H., Stahel R., Sabatier L., Pignon J. P., Tursz T., Le Chevalier T., Soria J. C., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy New England Journal of Medicine 2006 355 10 983 991 (Pubitemid 44343542)
16. Warnecke-Eberz U., Metzger R., Miyazono F., Baldus S. E., Neiss S., Brabender J., Schaefer H., Doerfler W., Bollschweiler E., Dienes H. P., Mueller R. P., Danenberg P. V., Hoelscher A. H., Schneider P. M., High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer Clinical Cancer Research 2004 10 11 3794 3799 (Pubitemid 38697614)
17. Bellmunt J., Paz-Ares L., Cuello M., Cecere F. L., Albiol S., Guillem V., Gallardo E., Carles J., Mendez P., de la Cruz J. J., Taron M., Rosell R., Baselga J., Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Annals of Oncology 2007 18 3 522 528 (Pubitemid 46359633)
18. Hoffmann A. C., Wild P., Leicht C., Bertz S., Danenberg K. D., Danenberg P. V., Sthr R., Stckle M., Lehmann J., Schuler M., Hartmann A., MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotheraphy Neoplasia 2010 12 8 628 636
19. Kim K. H., Do I. G., Kim H. S., Chang M. H., Kim H. S., Jun H. J., Uhm J., Yi S. Y., Lim D. H., Ji S. H., Park M. J., Lee J., Park S. H., Kwon G. Y., Lim H. Y., Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy Acta Pathologica, Microbiologica et Immunologica Scandinavica 2010 118 12 941 948
20. Kawashima A., Nakayama M., Kakuta Y., Abe T., Hatano K., Mukai M., Nagahara A., Nakai Y., Oka D., Takayama H., Yoshioka T., Hoshida Y., Itatani H., Nishimura K., Nonomura N., Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer Clinical Cancer Research 2011 17 8 2561 2569
21. Dong L. M., Potter J. D., White E., Ulrich C. M., Cardon L. R., Peters U., Genetic susceptibility to cancer: the role of polymorphisms in candidate genes Journal of the American Medical Association 2008 299 20 2423 2436 (Pubitemid 351749241)
22. García-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D. W., Tardn A., Serra C., Carrato A., Garca-Closas R., Lloreta J., Castao-Vinyals G., Yeager M., Welch R., Chanock S., Chatterjee N., Wacholder S., Samanic C., Tor M., Fernndez F., Real F. X., Rothman N., NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses The Lancet 2005 366 9486 649 659 (Pubitemid 41176017)
23. Vineis P., Talaska G., Malaveille C., Bartsch H., Martone T., Sithisarankul P., Strickland P., DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke International Journal of Cancer 1996 65 3 314 316 (Pubitemid 26059985)
24. Matullo G., Dunning A. M., Guarrera S., Baynes C., Polidoro S., Garte S., Autrup H., Malaveille C., Peluso M., Airoldi L., Veglia F., Gormally E., Hoek G., Krzyzanowski M., Overvad K., Raaschou-Nielsen O., Clavel-Chapelon F., Linseisen J., Boeing H., Trichopoulou A., Palli D., Krogh V., Tumino R., Panico S., Bueno-De-Mesquita H. B., Peeters P. H., Lund E., Pera G., Martinez C., Dorronsoro M., Barricarte A., Tormo M. J., Quiros J. R., Day N. E., Key T. J., Saracci R., Kaaks R., Riboli E., Vineis P., DNA repair polymorphisms and cancer risk in non-smokers in a cohort study Carcinogenesis 2006 27 5 997 1007
25. Matullo G., Guarrera S., Sacerdote C., Polidoro S., Davico L., Gamberini S., Karagas M., Casetta G., Rolle L., Piazza A., Vineis P., Polymorphisms/ haplotypes in DNA repair genes and smoking: a bladder cancer case-control study Cancer Epidemiology Biomarkers and Prevention 2005 14 11, part 1 2569 2578 (Pubitemid 41752717)
26. Ricceri F., Guarrera S., Sacerdote C., Polidoro S., Allione A., Fontana D., Destefanis P., Tizzani A., Casetta G., Cucchiarale G., Vineis P., Matullo G., ERCC1 haplotypes modify bladder cancer risk: a case-control study DNA Repair 2010 9 2 191 200
27. Stern M. C., Lin J., Figueroa J. D., Kelsey K. T., Kiltie A. E., Yuan J. M., Matullo G., Fletcher T., Benhamou S., Taylor J. A., Placidi D., Zhang Z. F., Steineck G., Rothman N., Kogevinas M., Silverman D., Malats N., Chanock S., Wu X., Karagas M. R., Andrew A. S., Nelson H. H., Bishop D. T., Sei C. S., Choudhury A., Barrett J. H., Elliot F., Corral R., Joshi A. D., Gago-Dominguez M., Cortessis V. K., Xiang Y. B., Gao Y. T., Vineis P., Sacerdote C., Guarrera S., Polidoro S., Allione A., Gurzau E., Koppova K., Kumar R., Rudnai P., Porru S., Carta A., Campagna M., Arici C., Park S. S. L., Garcia-Closas M., Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the International Consortium of Bladder Cancer Cancer Research 2009 69 17 6857 6864
28. Britten R. A., Liu D., Tessier A., Hutchison M. J., Murray D., ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells International Journal of Cancer 2000 89 5 453 457
29. Gossage L., Madhusudan S., Current status of excision repair cross complementing-group 1 (ERCC1) in cancer Cancer Treatment Reviews 2007 33 6 565 577 (Pubitemid 47355341)
30. Welsh C., Day R., McGurk C., Masters J. R. W., Wood R. D., Köberle B., Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines International Journal of Cancer 2004 110 3 352 361 (Pubitemid 38649885)
31. Liu Z. G., Chen H. Y., Cheng J. J., Chen Z. P., Li X. N., Xia Y. F., Relationship between methylation status of ERCC1 promoter andradiosensitivity in glioma cell lines Cell Biology International 2009 33 10 1111 1117
32. Yacoub A., McKinstry R., Hinman D., Chung T., Denta P., Hagan M. P., Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling Radiation Research 2003 159 4 439 452 (Pubitemid 36397765)
33. Ko J. C., Su Y. J., Lin S. T., Jhan J. Y., Ciou S. C., Cheng C. M., Lin Y. W., Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells Biochemical Pharmacology 2010 79 4 655 664
34. Chakravarti A., Winter K., Wu C. L., Kaufman D., Hammond E., Parliament M., Tester W., Hagan M., Grignon D., Heney N., Pollack A., Sandler H., Shipley W., Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group International Journal of Radiation Oncology Biology Physics 2005 62 2 309 317 (Pubitemid 40704444)
35. McConkey D. J., Choi W., Marquis L., Martin F., Williams M. B., Shah J., Svatek R., Das A., Adam L., Kamat A., Siefker-Radtke A., Dinney C., Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer Cancer and Metastasis Reviews 2009 28 3-4 335 344
36. Hagan M. P., Winter K. A., Kaufman D. S., Wajsman Z., Zietman A. L., Heney N. M., Toonkel L. M., Jones C. U., Roberts J. D., Shipley W. U., RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy International Journal of Radiation Oncology Biology Physics 2003 57 3 665 672 (Pubitemid 37194292)
37. Shipley W. U., Prout G. R. Jr., Einstein A. B., Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery Journal of the American Medical Association 1987 258 7 931 935 (Pubitemid 17125826)
38. Kaufman D. S., Winter K. A., Shipley W. U., Heney N. M., Chetner M. P., Souhami L., Zlotecki R. A., Sause W. T., True L. D., The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response Oncologist 2000 5 6 471 476
39. Kaufman D. S., Winter K. A., Shipley W. U., Heney N. M., Wallace H. J., Toonkel L. M., Zietman A. L., Tanguay S., Sandler H. M., Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy Urology 2009 73 4 833 837
40. Rödel C., Grabenbauer G. G., Kühn R., Papadopoulos T., Dunst J., Meyer M., Schrott K. M., Sauer R., Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results Journal of Clinical Oncology 2002 20 14 3061 3071 (Pubitemid 34791095)
41. Rödel C., Grabenbauer G. G., Rödel F., Birkenhake S., Khn R., Martus P., Zrcher T., Frsich D., Papadopoulos T., Dunst J., Schrott K. M., Sauer R., Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation International Journal of Radiation Oncology Biology Physics 2000 46 5 1213 1221 (Pubitemid 30139433)
42. Matsumoto H., Wada T., Fukunaga K., Yoshihiro S., Matsuyama H., Naito K., Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer Japanese Journal of Clinical Oncology 2004 34 3 124 130 (Pubitemid 43102903)
43. Sakano S., Hinoda Y., Sasaki M., Wada T., Matsumoto H., Eguchi S., Shinohara A., Kawai Y., Hara T., Nagao K., Hara T., Naito K., Matsuyama H., Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer Pharmacogenomics 2010 11 10 1377 1387
44. Boone J. J. M., Bhosle J., Tilby M. J., Hartley J. A., Hochhauser D., Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents Molecular Cancer Therapeutics 2009 8 11 3015 3023
45. Fleischmann A., Rotzer D., Seiler R., Studer U. E., Thalmann G. N., Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours European Urology 2011 60 2 350 357
46. Matsumura N., Nakamura Y., Kohjimoto Y., Inagaki T., Nanpo Y., Yasuoka H., Ohashi Y., Hara I., The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy BJU International 2011 108 2 E110 E116
47. Maréchal R., Mackey J. R., Lai R., Demetter P., Peeters M., Polus M., Cass C. E., Young J., Salmon I., Devire J., Van Laethem J. L., Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapyin resected pancreatic adenocarcinoma Clinical Cancer Research 2009 15 8 2913 2919
48. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J. D., Dumontet C., Cass C., Lai R., Mackey J. R., The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clinical Cancer Research 2004 10 20 6956 6961 (Pubitemid 39383046)
49. Hsu D. S. S., Lan H. Y., Huang C. H., Tai S. K., Chang S. Y., Tsai T. L., Chang C. C., Tzeng C. H., Wu K. J., Kao J. Y., Yang M. H., Regulation of excision repair cross-complementation group 1 by snail contributes to cisplatin resistance in head and neck cancer Clinical Cancer Research 2010 16 18 4561 4571
50. Arumugam T., Ramachandran V., Fournier K. F., Wang H., Marquis L., Abbruzzese J. L., Gallick G. E., Logsdon C. D., McConkey D. J., Choi W., Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Research 2009 69 14 5820 5828
51. Sanchez-Carbayo M., Socci N. D., Lozano J., Saint F., Cordon-Cardo C., Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays Journal of Clinical Oncology 2006 24 5 778 789 (Pubitemid 46622045)
52. Baumgart E., Cohen M. S., Silva Neto B., Jacobs M. A., Wotkowicz C., Rieger-Christ K. M., Biolo A., Zeheb R., Loda M., Libertino J. A., Summerhayes I. C., Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors Clinical Cancer Research 2007 13 6 1685 1694 (Pubitemid 46952933)
53. Sayan A. E., Griffiths T. R., Pal R., Browne G. J., Ruddick A., Yagci T., Edwards R., Mayer N. J., Qazi H., Goyal S., Fernandez S., Straatman K., Jones G. D. D., Bowman K. J., Colquhoun A., Mellon J. K., Kriajevska M., Tulchinsky E., SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer Proceedings of the National Academy of Sciences of the United States of America 2009 106 35 14884 14889
54. Soria J. C., ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial Journal of Clinical Oncology 2007 25 19 2648 2649